Shopping Cart 0
Cart Subtotal
USD 0

Nuformix Plc (NFX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Nuformix Plc (Nuformix), formerly Levrett plc, is a pharmaceutical company which develops cocrystal forms of approved small molecules. Its product candidates which are in clinical and pre-clinical development include NXP001, NXP002, and NXP003 for the treatment of oncology supportive care and fibrosis. Nuformix uses cocrystal technology to re-engineer crystallized drug with pharmaceutically acceptable inactive ingredients, resulting multi-component crystalline drug substances. It develops and manufactures products in reprofiling, supergenerics and emerging markets areas. The company conducts research and development programmes and seeks partnerships to utilize in pharmaceutical cocrystal technology. Nuformix is headquartered in Cambridge, the UK.

Nuformix Plc (NFX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Nuformix Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Nuformix Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Nuformix Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Nuformix Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Nuformix Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Nuformix Plc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Quotient Clinical Enters into Agreement Nuformix 10

Nuformix Enters into Agreement with FibroFind 11

Nuformix Extends Agreement with Onyx Scientific 12

Nuformix Enters into Agreement with Magnus Life Science 13

Licensing Agreements 14

Shanghai Newsummit Biopharma Enters into Licensing Agreement with Nuformix 14

Nuformix Extends Licensing Agreement with Dynasty Biotech for NX007 15

Nuformix Enters into Licensing Agreement with Dynasty Biotech 16

Acquisition 17

Levrett Acquires Nuformix in Reverse Takeover Transaction 17

Nuformix Plc-Key Competitors 18

Nuformix Plc-Key Employees 19

Nuformix Plc-Locations And Subsidiaries 20

Head Office 20

Other Locations & Subsidiaries 20

Recent Developments 21

Financial Announcements 21

Jul 26, 2018: Nuformix: final results for year ended 31 March 2018 21

Corporate Communications 26

Dec 14, 2017: Nuformix: Advisory Panel Appointments Chaired by Dr Andy Richards 26

Product News 27

01/31/2018: Positive Results from NXP002 Pilot Study in Lung and Liver Fibrosis 27

Other Significant Developments 28

Jul 02, 2018: Nuformix Announces Operational Update 28

Oct 13, 2017: Levrett announces name change to Nuformix 29

Appendix 30

Methodology 30

About GlobalData 30

Contact Us 30

Disclaimer 30


List Of Figure

List of Figures

Nuformix Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Nuformix Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Nuformix Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Nuformix Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Nuformix Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Nuformix Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Nuformix Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Nuformix Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Nuformix Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Nuformix Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Nuformix Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Nuformix Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Nuformix Plc, Deals By Therapy Area, 2012 to YTD 2018 8

Nuformix Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Quotient Clinical Enters into Agreement Nuformix 10

Nuformix Enters into Agreement with FibroFind 11

Nuformix Extends Agreement with Onyx Scientific 12

Nuformix Enters into Agreement with Magnus Life Science 13

Shanghai Newsummit Biopharma Enters into Licensing Agreement with Nuformix 14

Nuformix Extends Licensing Agreement with Dynasty Biotech for NX007 15

Nuformix Enters into Licensing Agreement with Dynasty Biotech 16

Levrett Acquires Nuformix in Reverse Takeover Transaction 17

Nuformix Plc, Key Competitors 18

Nuformix Plc, Key Employees 19

Nuformix Plc, Subsidiaries 20

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Nuformix Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.